Elisa Agostinetto/X
Jan 5, 2025, 18:21
Elisa Agostinetto: Drug-drug interactions between palbociclib and PPI in breast cancer
Elisa Agostinetto, Medical Research Fellow at the University Hospital of Brussels, shared a post on LinkedIn:
“What is the impact of drug-drug interactions between palbociclib and proton pump inhibitors (PPI) in breast cancer?
Can PPI use explain why the PALLAS trial was negative?
Now out in ESMO our analysis of PALLAS exploring this question.”
Authors: E. Agostinetto, G. Pfeiler, D. Hlauschek, E.L. Mayer, M. Lambertini, E. de Azambuja, M. Bellet-Ezquerra, J.L. Meisel, G. Rubovszky, N. Zdenkowski, Y. Novik, M. Ruiz-Borrego, K.A. Gelmon, E.P. Mamounas, H. Iwata, D.R. Lu, L. Soelkner, C. Fesl, M. Gnant, A. DeMichele
A DeMichele
Breast Cancer
C. Fesl
cancer
D. Hlauschek
D.R. Lu
E. Agostinetto
E. de Azambuja
E.L. Mayer
E.P. Mamounas
Elisa Agostinetto
G. Pfeiler
G. Rubovszky
H. Iwata
J.L. Meisel
K.A. Gelmon
L. Soelkner
M. Bellet-Ezquerra
M. Gnant
M. Lambertini
M. Ruiz-Borrego
N. Zdenkowski
OncoDaily
Oncology
palbociclib
PALLAS trial
Y. Novik
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 9, 2025, 13:49
May 9, 2025, 13:37
May 9, 2025, 12:49
May 9, 2025, 12:42